TOPOISOMERASE II-ALPHA CONTENT AND TOPOISOMERASE-II CATALYTIC ACTIVITY CANNOT EXPLAIN DRUG SENSITIVITIES TO TOPOISOMERASE-II INHIBITORS IN LUNG-CANCER CELL-LINES
K. Yamazaki et al., TOPOISOMERASE II-ALPHA CONTENT AND TOPOISOMERASE-II CATALYTIC ACTIVITY CANNOT EXPLAIN DRUG SENSITIVITIES TO TOPOISOMERASE-II INHIBITORS IN LUNG-CANCER CELL-LINES, Cancer chemotherapy and pharmacology, 39(3), 1997, pp. 192-198
Purpose: Topoisomerase II alpha content, topoisomerase II catalytic ac
tivity and drug sensitivities to the topoisomerase II inhibitors, doxo
rubicin and etoposide, were examined in a panel of 14 unselected human
lung cancer cell lines in order to determine the relationship between
topoisomerase II and drug sensitivities to the topoisomerase II inhib
itors. Methods: Drug sensitivities were determined using a microcultur
e tetrazolium assay. The topoisomerase II alpha levels were determined
by Western blot analysis and the topoisomerase II catalytic activity
was determined using a decatenation assay of kinetoplast DNA, using nu
clear protein from cells of each cell line. Results: Drug sensitivity
tests revealed that small-cell lung cancer (SCLC) cell lines were more
sensitive to drugs than non-small-cell lung cancer (NSCLC) cell lines
. The relative topoisomerase II alpha levels and relative topoisomeras
e II catalytic activity from SCLC cell lines (mean +/- SD 0.89 +/- 0.5
4 and 5.3 +/- 3.4, respectively) were slightly higher than those from
NSCLC cell lines (0.78 +/- 0.56 and 4.0 +/- 2.8, respectively), but th
e differences were not statistically significant, and not sufficient t
o account for the variation in drug sensitivities. Moreover, no clear
association was observed between the topoisomerase II alpha levels or
the topoisomerase II catalytic activity and drug sensitivities in the
cell lines studied. Conclusions: These findings suggest that the diffe
rence in drug sensitivities to doxorubicin and etoposide in human lung
cancer cell lines might not be explainable by the topoisomerase II al
pha levels and topoisomerase II catalytic activity. Moreover, our resu
lts suggest that the topoisomerase II alpha levels and topoisomerase I
I catalytic activity may play a minor role in the determination of cli
nical drug resistance of human lung cancers.